Genetic Testing Practices in Infants with Congenital Heart Disease

Jessica A. Connor, Robert B. Hinton, Erin M. Miller, Kristen L. Sund, Jennifer G. Ruschman, Stephanie Ware

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Clinical genetic testing is expanding rapidly, but the application of new testing has not been reported in an unselected, comprehensive congenital heart disease (CHD) patient population. This study aims to identify cytogenetic testing practices and diagnostic yield in infants with CHD as an important first step toward understanding clinical utility of dedicated cytogenetic testing. We hypothesized that chromosome microarray analysis (CMA) would identify genetic abnormalities underlying both syndromic and isolated CHD. Design: This is a single institution retrospective study that characterizes cytogenetic testing practices and diagnostic yield for all cytogenetic testing in each infant identified with CHD over a 32-month period. CHD was classified by type, complexity, and presence or absence of extracardiac anomalies. Results: Among the 1087 infants identified with CHD by echocardiogram, 277 infants (25%) had some form of cytogenetic testing, including karyotype, fluorescence in situ hybridization, and/or CMA. Forty-one percent of infants who had cytogenetic testing had more than one test. CMA was performed in 121 patients (11%), and abnormalities (both clinically significant and variants of unknown significance) were identified in 35/121 (29%). Forty-nine percent of CMA abnormalities were in patients with apparently isolated nonsyndromic CHD. Conclusions: This single institution study identified that only 25% of infants with CHD underwent cytogenetic testing, indicating possible underutilization of testing in this age group. The high multiple testing rate indicates a need for improved guidelines for cost effective testing approaches. The diagnostic yield in this study suggests that CMA is a particularly useful first screening test when a specific syndrome is not clinically identifiable. Larger studies investigating cardiac lesion-specific diagnostic yield in isolated CHD are warranted.

Original languageEnglish (US)
Pages (from-to)158-167
Number of pages10
JournalCongenital Heart Disease
Volume9
Issue number2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Genetic Testing
Heart Diseases
Cytogenetics
Microarray Analysis
Chromosomes
Fluorescence In Situ Hybridization
Karyotype
Retrospective Studies
Age Groups
Guidelines
Costs and Cost Analysis

Keywords

  • Cardiovascular Malformation
  • Chromosome Microarray
  • Cytogenetic Testing
  • Genetic Syndrome
  • Infant

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Connor, J. A., Hinton, R. B., Miller, E. M., Sund, K. L., Ruschman, J. G., & Ware, S. (2014). Genetic Testing Practices in Infants with Congenital Heart Disease. Congenital Heart Disease, 9(2), 158-167. https://doi.org/10.1111/chd.12112

Genetic Testing Practices in Infants with Congenital Heart Disease. / Connor, Jessica A.; Hinton, Robert B.; Miller, Erin M.; Sund, Kristen L.; Ruschman, Jennifer G.; Ware, Stephanie.

In: Congenital Heart Disease, Vol. 9, No. 2, 2014, p. 158-167.

Research output: Contribution to journalArticle

Connor, JA, Hinton, RB, Miller, EM, Sund, KL, Ruschman, JG & Ware, S 2014, 'Genetic Testing Practices in Infants with Congenital Heart Disease', Congenital Heart Disease, vol. 9, no. 2, pp. 158-167. https://doi.org/10.1111/chd.12112
Connor, Jessica A. ; Hinton, Robert B. ; Miller, Erin M. ; Sund, Kristen L. ; Ruschman, Jennifer G. ; Ware, Stephanie. / Genetic Testing Practices in Infants with Congenital Heart Disease. In: Congenital Heart Disease. 2014 ; Vol. 9, No. 2. pp. 158-167.
@article{e051b1a0335741caaf97bbbb51acef01,
title = "Genetic Testing Practices in Infants with Congenital Heart Disease",
abstract = "Objective: Clinical genetic testing is expanding rapidly, but the application of new testing has not been reported in an unselected, comprehensive congenital heart disease (CHD) patient population. This study aims to identify cytogenetic testing practices and diagnostic yield in infants with CHD as an important first step toward understanding clinical utility of dedicated cytogenetic testing. We hypothesized that chromosome microarray analysis (CMA) would identify genetic abnormalities underlying both syndromic and isolated CHD. Design: This is a single institution retrospective study that characterizes cytogenetic testing practices and diagnostic yield for all cytogenetic testing in each infant identified with CHD over a 32-month period. CHD was classified by type, complexity, and presence or absence of extracardiac anomalies. Results: Among the 1087 infants identified with CHD by echocardiogram, 277 infants (25{\%}) had some form of cytogenetic testing, including karyotype, fluorescence in situ hybridization, and/or CMA. Forty-one percent of infants who had cytogenetic testing had more than one test. CMA was performed in 121 patients (11{\%}), and abnormalities (both clinically significant and variants of unknown significance) were identified in 35/121 (29{\%}). Forty-nine percent of CMA abnormalities were in patients with apparently isolated nonsyndromic CHD. Conclusions: This single institution study identified that only 25{\%} of infants with CHD underwent cytogenetic testing, indicating possible underutilization of testing in this age group. The high multiple testing rate indicates a need for improved guidelines for cost effective testing approaches. The diagnostic yield in this study suggests that CMA is a particularly useful first screening test when a specific syndrome is not clinically identifiable. Larger studies investigating cardiac lesion-specific diagnostic yield in isolated CHD are warranted.",
keywords = "Cardiovascular Malformation, Chromosome Microarray, Cytogenetic Testing, Genetic Syndrome, Infant",
author = "Connor, {Jessica A.} and Hinton, {Robert B.} and Miller, {Erin M.} and Sund, {Kristen L.} and Ruschman, {Jennifer G.} and Stephanie Ware",
year = "2014",
doi = "10.1111/chd.12112",
language = "English (US)",
volume = "9",
pages = "158--167",
journal = "Congenital Heart Disease",
issn = "1747-079X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Genetic Testing Practices in Infants with Congenital Heart Disease

AU - Connor, Jessica A.

AU - Hinton, Robert B.

AU - Miller, Erin M.

AU - Sund, Kristen L.

AU - Ruschman, Jennifer G.

AU - Ware, Stephanie

PY - 2014

Y1 - 2014

N2 - Objective: Clinical genetic testing is expanding rapidly, but the application of new testing has not been reported in an unselected, comprehensive congenital heart disease (CHD) patient population. This study aims to identify cytogenetic testing practices and diagnostic yield in infants with CHD as an important first step toward understanding clinical utility of dedicated cytogenetic testing. We hypothesized that chromosome microarray analysis (CMA) would identify genetic abnormalities underlying both syndromic and isolated CHD. Design: This is a single institution retrospective study that characterizes cytogenetic testing practices and diagnostic yield for all cytogenetic testing in each infant identified with CHD over a 32-month period. CHD was classified by type, complexity, and presence or absence of extracardiac anomalies. Results: Among the 1087 infants identified with CHD by echocardiogram, 277 infants (25%) had some form of cytogenetic testing, including karyotype, fluorescence in situ hybridization, and/or CMA. Forty-one percent of infants who had cytogenetic testing had more than one test. CMA was performed in 121 patients (11%), and abnormalities (both clinically significant and variants of unknown significance) were identified in 35/121 (29%). Forty-nine percent of CMA abnormalities were in patients with apparently isolated nonsyndromic CHD. Conclusions: This single institution study identified that only 25% of infants with CHD underwent cytogenetic testing, indicating possible underutilization of testing in this age group. The high multiple testing rate indicates a need for improved guidelines for cost effective testing approaches. The diagnostic yield in this study suggests that CMA is a particularly useful first screening test when a specific syndrome is not clinically identifiable. Larger studies investigating cardiac lesion-specific diagnostic yield in isolated CHD are warranted.

AB - Objective: Clinical genetic testing is expanding rapidly, but the application of new testing has not been reported in an unselected, comprehensive congenital heart disease (CHD) patient population. This study aims to identify cytogenetic testing practices and diagnostic yield in infants with CHD as an important first step toward understanding clinical utility of dedicated cytogenetic testing. We hypothesized that chromosome microarray analysis (CMA) would identify genetic abnormalities underlying both syndromic and isolated CHD. Design: This is a single institution retrospective study that characterizes cytogenetic testing practices and diagnostic yield for all cytogenetic testing in each infant identified with CHD over a 32-month period. CHD was classified by type, complexity, and presence or absence of extracardiac anomalies. Results: Among the 1087 infants identified with CHD by echocardiogram, 277 infants (25%) had some form of cytogenetic testing, including karyotype, fluorescence in situ hybridization, and/or CMA. Forty-one percent of infants who had cytogenetic testing had more than one test. CMA was performed in 121 patients (11%), and abnormalities (both clinically significant and variants of unknown significance) were identified in 35/121 (29%). Forty-nine percent of CMA abnormalities were in patients with apparently isolated nonsyndromic CHD. Conclusions: This single institution study identified that only 25% of infants with CHD underwent cytogenetic testing, indicating possible underutilization of testing in this age group. The high multiple testing rate indicates a need for improved guidelines for cost effective testing approaches. The diagnostic yield in this study suggests that CMA is a particularly useful first screening test when a specific syndrome is not clinically identifiable. Larger studies investigating cardiac lesion-specific diagnostic yield in isolated CHD are warranted.

KW - Cardiovascular Malformation

KW - Chromosome Microarray

KW - Cytogenetic Testing

KW - Genetic Syndrome

KW - Infant

UR - http://www.scopus.com/inward/record.url?scp=84897572707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897572707&partnerID=8YFLogxK

U2 - 10.1111/chd.12112

DO - 10.1111/chd.12112

M3 - Article

VL - 9

SP - 158

EP - 167

JO - Congenital Heart Disease

JF - Congenital Heart Disease

SN - 1747-079X

IS - 2

ER -